Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.68 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.68 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.56 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.56 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | PRKACA | P17612 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.54 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.54 |
| ▸ | MST1R | Q04912 | 1/20 | 0.54 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.54 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30524061 | 1.00 | PARP1 (0.68) | PARP1PARP10CLK4NTRK2DYRK1B | |
| SCHEMBL29984992 | 0.85 | CLK4 (0.73) | PARP1PARP10CLK4NTRK2DYRK1B | |
| SCHEMBL164795 | 0.84 | GRM5 (0.68) | PARP1PARP10CLK4NTRK2DYRK1B | |
| SCHEMBL30545957 | 0.84 | GRM5 (0.68) | PARP1PARP10CLK4NTRK2DYRK1B | |
| SCHEMBL30915406 | 0.84 | TDP2 (0.59) | PARP1PARP10CLK4NTRK2DYRK1B | |
| SCHEMBL23952279 | 0.81 | PARP10 (1.00) | PARP1PARP10GRM5FABP6SRD5A1 | |
| SCHEMBL29914810 | 0.81 | PARP10 (1.00) | PARP1PARP10GRM5FABP6SRD5A1 | |
| SCHEMBL30459664 | 0.81 | PARP1 (0.59) | PARP1PARP10CLK4NTRK2DYRK1B | |
| SCHEMBL1438328 | 0.78 | TDP2 (0.59) | PARP1PARP10CLK4NTRK2DYRK1B | |
| SCHEMBL30765133 | 0.78 | TDP2 (0.59) | PARP1PARP10CLK4NTRK2DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | VERNALIS (R&D) LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| US-11945805-B2 | Inhibitors of CXCR2 | CHEMOCENTRYX, INC (US) | 2024-04-02 | — | — | US | disclosed |
| WO-2024061340-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-03-28 | — | — | WO | disclosed |
| EP-3383386-B1 | MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX INC (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-112409332-B | Triazole derivative and application thereof in medicines | 广东东阳光药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4277892-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2023-11-22 | — | — | EP | disclosed |
| US-11820759-B2 | Modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820759-B2 | Modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20170144996-A1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX, INC. | 2017-05-25 | — | — | US | disclosed |
| EP-2078004-B1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2152664-B1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-03 | — | — | EP | disclosed |
| EP-1209754-B1 | NON-AQUEOUS ELECTROLYTE CELL | PANASONIC CORP (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-7879890-B2 | hydantoin derivatives that can inhibit matrix metalloproteinases and tumor necrosis factor alpha-converting enzyme, to prevent the release of tumor necrosis factor; treatment of septic shock, reperfusion injuries, meningitis, psoriasis, arthritis, inflammatory bowel disease and ankylosing spondylitis | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-7687527-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090137586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-7482370-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| WO-2007084415-A2 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| US-5254578-A | Cardiovascular disorders | SANKYO COMPANY, LIMITED (JP) | 1993-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BAX, BCL2A1 | PARP1 201/4885PARP10 505/4885CLK4 3812/4885 |
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | PARP1 600/4885PARP10 670/4885CLK4 3576/4885 |
| US-20170144996-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR3, CXCR1 | PARP1 3337/4885PARP10 3102/4885CLK4 3217/4885 |
| US-11820759-B2 | Modulators of chemokine receptors | CCR5, CXCR3, CCR2 | PARP1 3322/4885PARP10 2928/4885CLK4 4161/4885 |
| US-20090137586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | PARP1 2070/4885PARP10 2816/4885CLK4 3678/4885 |
| US-11945805-B2 | Inhibitors of CXCR2 | CXCR2, CXCR3, CXCR1 | PARP1 3337/4885PARP10 3102/4885CLK4 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.